Kod: 04551202
European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supr ... więcej
573.28 zł
Potrzebujesz więcej egzemplarzy?Jeżeli jesteś zainteresowany zakupem większej ilości egzemplarzy, skontaktuj się z nami, aby sprawdzić ich dostępność.
Za ten zakup dostaniesz 331 punkty
European and American drug regulators govern a multi-billion-dollar pharmaceutical industry selling its products on the world's two largest medicines markets. This is the first book to investigate how effectively American and supranational EU governments have regulated innovative pharmaceuticals regarding public health during the neo-liberal era of the last 30 years. Drawing on years of fieldwork, the authors demonstrate that pharmaceutical regulation and innovation have been misdirected by commercial interests and misconceived ideologies, which induced a deregulatory political culture contrary to health interests. They dismantle the myth that pharmaceutical innovations necessarily equate with therapeutic advances and explain how it has been perpetuated in the interests of industry by corporate bias within the regulatory state, unwarranted expectations of promissory science, and the emergent patient-industry complex. Endemic across both continents, the misadventures of pharmaceutical deregulation are shown to span many therapeutic areas, including cancer, diabetes and irritable bowel syndrome. The authors propose political changes needed to redirect pharmaceutical regulation in the interests of health.
Kategoria Książki po angielsku Law Laws of Specific jurisdictions Social law
573.28 zł
Od roku 2008 obsłużyliśmy wielu miłośników książek, ale dla nas każdy był tym wyjątkowym.
Copyright! ©2008-24 libristo.pl Wszelkie prawa zastrzeżonePrywatnieCookies
Dobre na wszystkich stronach
Koszyk ( pusty )